Clinical trials: Metabolic Alcohol-Related Liver Disease
Alcoholic Liver Cirrhosis, Ascites
Prevention of Decompensation in Liver Cirrhosis
The purpose of this study is to determine whether losartan, an angiotensin II blocker prevents the sodium retention in patients with liver cirrhosis and by that reduces the fluid retention.
- Trial name
- NCT00239096
- Testing
- losartan (drug)
- Where
- Denmark
- Volunteers
- 100 people
- Sponsor
- Odense University Hospital
Binge Drinking, Liver Injury
Metabolic Changes in Healthy Subjects with Acute Binge Drink
The goal of this double-blinded, randomized trial is to investigate the effects of acute binge drinking on liver function, liver fat content, and lipid metabolism in healthy young subjects.
- Conditions
- Binge Drinking, Liver Injury, Hepatic Steatosis
- Trial name
- MeABD (NCT06298318)
- Testing
- Vodka, water
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Zhejiang Chinese Medical University
Liver Cirrhosis
Faecal Microbiota Transplantation for Liver Cirrhosis
The purpose is to investigate the effect of faecal microbiota transplantation (FMT) on complications, progression, and mortality of patients with liver cirrhosis.
- Trial name
- CHiFT (NCT04932577)
- Testing
- Faecal microbiota transplantation
- Where
- Denmark
- Volunteers
- 220 people
- Sponsor
- University of Aarhus
Adiposity, Fatty Liver
GLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease
There is evidence that alcoholic beverage consumption significantly interacts with food energy intake. Furthermore, there is accumulating evidence showing independent, combined, and modifying effects of alcohol and metabolic…
- Conditions
- Adiposity, Fatty Liver, Alcohol Use Disorder
- Trial name
- GLP-1 RA (NCT06546384)
- Testing
- Semaglutide, Weight reduction recommendations (nutritional and exercise)
- Where
- Switzerland
- Volunteers
- 64 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
HIV, Metabolic Syndrome
Comorbidities and Virologic Outcome Among Patients on Anti-retroviral Therapy in Rural Lesotho
This study is conducted in a cohort of HIV-positive patients on first-line anti-retroviral therapy (ART) in rural health facilities in Lesotho, Southern Africa.
- Conditions
- HIV, Metabolic Syndrome, Depression, Alcoholism
- Trial name
- NCT02126696
- Where
- 2 sites in Lesotho
- Volunteers
- 1,754 people
- Sponsor
- Swiss Tropical & Public Health Institute
Alcoholic Liver Disease
THE IMMUNOLOGICAL EFFECTS AND METABOLIC TOLERANCE OF LIPID INFUSION IN PATIENTS WITH CIRRHOSIS.
The study will be an experimental pre-post trial in which patients with ethanol related liver disease (both severe alcoholic hepatitis and decompensated ) admitted in our institute from Jun 2013-Dec 2014 will be enrolled in the…
- Trial name
- NCT02381769
- Testing
- Soybean based lipid emulsion
- Where
- India
- Volunteers
- 55 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Alcoholic Liver Disease
Ethanol Induces Skeletal Muscle Autophagy
In this study we plan to demonstrate that ethanol induces skeletal muscle autophagy to degrade MAA adducts.
- Trial name
- NCT03209791
- Testing
- Biopsies
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- The Cleveland Clinic
Crohn Disease, Ulcerative Colitis
Safety and Efficacy of Fecal Microbiota Transplantation
The gut microbiota is critical to health and functions with a level of complexity comparable to that of an organ system. Dysbiosis, or alterations of this gut microbiota ecology, have been implicated in a number of disease…
- Conditions
- Crohn Disease, Ulcerative Colitis, Celiac Disease, Irritable Bowel Syndrome
- Trial name
- NCT04014413
- Testing
- Fecal Microbiota Transplantation
- Where
- Hong Kong
- Volunteers
- 450 people
- Sponsor
- Chinese University of Hong Kong
Iron Overload, Metabolic Syndrome X
Quantification of Liver Iron Overload and Steatosis Using Magnetic Resonance Imaging
Iron excess is increasingly regarded as an important cofactor in the morbidity attributed to many disorders. Assessment of body iron stores by measurement of serum ferritin concentrations has poor specificity and the most…
- Conditions
- Iron Overload, Metabolic Syndrome X, Hepatitis B, Hepatitis C
- Trial name
- SURFER (NCT00401336)
- Testing
- Magnetic resonance imaging multiecho gradient-echo sequence
- Where
- 10 sites in France, Spain
- Volunteers
- 250 people
- Sponsor
- Rennes University Hospital
Binge Drinking, Liver Injury
Metabolic Changes Induced by NMN in Healthy Subjects With Acute Binge Drink
The goal of this double-blinded, randomized, crossover trial is to investigate the effects of NMN supplementation on liver function, liver fat content and lipid metabolism in healthy young subjects with acute binge drink.
- Conditions
- Binge Drinking, Liver Injury, Nutritional Supplementation, Hepatic Steatosis
- Trial name
- NMN-MeABD (NCT05882214)
- Testing
- β-nicotinamide Mononucleotide, Maltodextrin
- Where
- China
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Zhejiang Chinese Medical University
Steatotic Liver Disease, MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)
Long-term Follow-up to Determine Outcome in Liver Disease (LOVE Study)
The rational to conduct the LOVE study builds on the lack of available data on outcomes in steatotic liver disease in well characterized patients over a time frame of several years.
- Conditions
- Steatotic Liver Disease, MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis), Steatotic Liver Disease of Mixed Origin (MetALD), ALD - Alcoholic Liver Disease
- Trial name
- LOVE (NCT06907563)
- Where
- 4 sites in France, Germany and 2 more
- Volunteers
- 30,000 people
- Sponsor
- Universität des Saarlandes
Liver Cirrhosis
Apixaban to Prevent Decompensation of Early Liver Cirrhosis Trial
Liver disease is the only common cause of death that is increasing in numbers. Once people develop severe scarring (cirrhosis), there are no medications proven to help them live longer, healthier lives.
- Trial name
- APEACH (NCT07726693)
- Testing
- Apixaban 2.5 mg twice daily
- Volunteers
- 1,142 people
- Sponsor
- University College, London
Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD), Hepatomegaly
Gepaktiv vs UDCA and Ademetionine in MAFLD With Hepatomegaly
This study compares the effectiveness of the dietary supplement Gepaktiv with standard medications (UDCA and Ademetionine) in patients with fatty liver disease (MAFLD) and liver enlargement (hepatomegaly).
- Conditions
- Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD), Hepatomegaly, Nonalcoholic Fatty Liver (NAFL), Nonalcoholic Fatty Liver Disease (NAFLD)
- Trial name
- HEPACT (NCT07068191)
- Testing
- Dietary supplement "Gepaktiv", UDCA (Ursodeoxycholic acid), Ademetionine
- Where
- Russia
- Volunteers
- 90 people
- Sponsor
- Phenomen Pharma
Alcohol-related Liver Disease, Alcohol Use Disorder
Study of the Drivers of Late Diagnosis of Alcohol Related Diseases, Alone or in Combination With Metabolic Dysfunconal Associated Fatty Liver Disease, Implementation and Evaluation of Itnerventions to Reduce Its Burden.
Excessive alcohol use is a leading risk factor for preventable disability and death. Alcohol-related liver disease (ALD) is one of the better-known detrimental consequences of alcohol abuse and is the main cause of…
- Conditions
- Alcohol-related Liver Disease, Alcohol Use Disorder, Metabolic and Alcohol Related/Associated Liver Disease, Metabolic Disfunction Associated Steatotic Liver Disease
- Trial name
- StopALD (NCT06403332)
- Testing
- brief intervention
- Where
- 2 sites in Spain
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Coronary Artery Disease, Congestive Heart Failure
Prognostic Indicators as Provided by the EPIC ClearView
The objective of this study is to determine whether the finger tip images captured by the EPIC ClearView device, when analyzed via the ClearView software, produce a Response Scale that characterizes trends consistent with known…
- Conditions
- Coronary Artery Disease, Congestive Heart Failure, Valvular Heart Disease, Atrial Fibrillation
- Trial name
- GBMC (NCT01476995)
- Where
- United States
- Volunteers
- 353 people, healthy volunteers welcome
- Sponsor
- Epic Research & Diagnostics, Inc.
Liver Diseases, Alcoholic, Fatty Liver
Personalized Transcranial Magnetic Stimulation (TMS) for Metabolic Dysfunction and Alcohol-Related Liver Disease
The goal of this clinical trial is to learn if repetitive Transcranial Magnetic Stimulation (rTMS), a non-invasive brain stimulation technique, works to treat Metabolic dysfunction-associated and alcohol-associated liver disease…
- Conditions
- Liver Diseases, Alcoholic, Fatty Liver, Metabolic Syndrome
- Trial name
- P-TMS MetALD (NCT07399600)
- Testing
- Individually Targeted rTMS, Conventional rTMS
- Where
- China
- Volunteers
- 105 people
- Sponsor
- The Affiliated Hospital of Hangzhou Normal University
Liver Cirrhosis
A PROspective Faecal MIcrobiota tranSplantation Trial to Improve outcomEs in Patients With Cirrhosis
A feasibility trial called PROFIT has previously shown that FMT administered endoscopically into the jejunum in patients with cirrhosis is safe and feasible and have identified some potential mechanisms of action that warrant…
- Trial name
- PROMISE (NCT06461208)
- Testing
- Encapsulated FMT
- Where
- 23 sites in United Kingdom
- Volunteers
- 300 people
- Sponsor
- King's College London
Alcoholic Hepatitis
Randomized, Controlled Trial of S-adenosylmethionine in Alcoholic Liver Disease
Background: Alcoholic liver disease is one of the most important causes of chronic liver disease in this country. There is currently no treatment for chronic alcoholic liver disease other than abstinence.
- Trial name
- RCT SAMe (NCT00851981)
- Testing
- SAMe
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Loma Linda University
Lysosomal Acid Lipase Deficiency, Wolman Disease
Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Sebelipase Alfa in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency
This was an open-label, repeat-dose, intra-participant dose-escalation study of SBC-102 (sebelipase alfa) in children with growth failure due to lysosomal acid lipase (LAL) Deficiency.
- Trial name
- NCT01371825
- Testing
- Sebelipase alfa (SBC-102)
- Where
- 7 sites in United States, Egypt and 3 more
- Volunteers
- 9 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Liver Diseases, Alcoholic, Metabolic Diseases
Multicentre Prospective Cohort Study of Patients With Chronic Alcoholic and/or Metabolic Liver Disease
Chronic alcoholic and metabolic liver diseases are the two main liver diseases in France. The long-term prognosis of these two diseases are not well known because main studies are retrospective and with only alcoholic patients.
- Trial name
- CALMET (NCT01237574)
- Testing
- Intervention according to the standard of care.
- Where
- 36 sites in France
- Volunteers
- 527 people
- Sponsor
- University Hospital, Bordeaux